CasNo.204656-20-2,Top Quality Peptide Liraglutide CAS 204656-20-2 Liraglutide Acetate,(204656-20-2) Suppliers

1 Gram	Negotiable

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,,MoneyGram

Keywords

Liraglutide Liraglutide Acetate cas 204656-20-2

Quick Details

Appearance:white powder
Application:for the treatment of type 2 diabetes
PackAge:aluminum foil bag, discreet packing
ProductionCapacity:1|Kilogram|Month
Storage:cool and dry place
Transportation:EMS,DHL,HK post,EUB,ETK,NL post,Germany post

Superiority:

1.high quality:

quality is life. quality is the most important element for all goods. we have a lab doing research in wuhan china. hplc and nmr is available if needed.

2.reasonable price:

we provide high quality products with competitive price in china. all customers are welcomed to send us inquiries and get quotation.

3.low moq:

no worry about the low moq, our moq is 1 gram or even lower.

4.good service.

fast response. we promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.

5. fast shipping and secure courier.

we promise to send out products and provide tracking number within 3 working days. and we send via different couriers based on different destination countries. we usually use nl post, hk post, germany post, eub, etk, etc.

Details:

Supply Pharmaceutical 99% Liraglutide Acetate CAS 204656-20-2

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. and E.U. under the brand name Saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

Function

Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.

In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:

1).It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.

2).It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).

3).It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.

4).It lowers blood triglyceride levels.